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Abstract
Background: Cells are constantly exposed to stresses from cellular metabolites as well as environmental genotoxins. 
DNA damage caused by these genotoxins can be efficiently fixed by DNA repair in cooperation with cell cycle 
checkpoints. Unrepaired DNA lesions can lead to cell death, gene mutation and cancer. The Rad1 protein, 
evolutionarily conserved from yeast to humans, exists in cells as monomer as well as a component in the 9-1-1 protein 
complex. Rad1 plays crucial roles in DNA repair and cell cycle checkpoint control, but its contribution to carcinogenesis 
is unknown.
Results: To address this question, we constructed mice with a deletion of Mrad1. Matings between heterozygous 
Mrad1 mutant mice produced Mrad1+/+ and Mrad1+/- but no Mrad1-/- progeny, suggesting the Mrad1 null is embryonic 
lethal. Mrad1+/- mice demonstrated no overt abnormalities up to one and half years of age. DMBA-TPA combinational 
treatment was used to induce tumors on mouse skin. Tumors were larger, more numerous, and appeared earlier on the 
skin of Mrad1+/- mice compared to Mrad1+/+ animals. Keratinocytes isolated from Mrad1+/- mice had significantly more 
spontaneous DNA double strand breaks, proliferated slower and had slightly enhanced spontaneous apoptosis than 
Mrad1+/+ control cells.
Conclusion: These data suggest that Mrad1 is important for preventing tumor development, probably through 
maintaining genomic integrity. The effects of heterozygous deletion of Mrad1 on proliferation and apoptosis of 
keratinocytes is different from those resulted from Mrad9 heterozygous deletion (from our previous study), suggesting 
that Mrad1 also functions independent of Mrad9 besides its role in the Mrad9-Mrad1-Mhus1 complex in mouse cells.
Background
Living organisms are continuously exposed to both physi-
ological and environmental DNA-damaging agents.
Eukaryotic cells have developed exquisite mechanisms
that monitor and coordinate cell cycle progression with
repair of DNA damage to maintain genome integrity.
Mutations in genes that play roles in cell cycle checkpoint
control and DNA repair are often associated with tumori-
genesis [1,2]. Rad9, Rad1 and Hus1 are a group of genes
conserved from yeast to human that play key roles in cell
cycle checkpoints and DNA repair [3-8]. Their protein
products form a heterotrimeric ring-like complex, called
9-1-1 [9-11]. It is believed that this complex is important
for the function of these three proteins in DNA repair as
well as activation of cell cycle checkpoints. It is not clear
whether Rad1, Rad9 and Hus1 also have distinct func-
tional activities independent of the heterotrimeric form.
The S. cerevisiae checkpoint protein Rad17, the ortho-
logue of human Rad1, forms a homocomplex in response
to treatment with DNA damaging agents, and the com-
plex is required for yeast survival after exposure to geno-
toxic agents [12]. Besides the existence of 9-1-1
heterotrimer in K562 and 293 human cells, a significant
amount of hRad1 also exists in monomeric form, but
monomeric hRad9 and hHus1 were not detectable in a
study by Karnitz's group [10] and in our unpublished
experiments in 293 human cells. These data suggest a
possibility that Rad1 in humans and mice might have dis-
tinct functions independent of the 9-1-1 heterotrimer.
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Increased expression of Rad9 was found in lung, breast
and prostate tumors, relative to normal corresponding
tissues [13-16]. High level of Hus1 expression correlates
with poor prognosis for ovarian tumors [17]. Knockdown
of Rad9 in prostate tumor cells correlates with reduction
o f  t u m o r i g e n i ci t y  i n  n u d e  m i c e  [ 1 6 ] .  Ra d 9  kn oc k d o wn
also suppresses growth of human lung adenocarcinoma
cells A549 and PC3 [18]. It is likely that increased Rad9
expression is needed for proliferation of tumor cells by
mechanisms such as getting beyond (tolerating) onco-
gene-induced replicative stress and enhancing DNA
repair capability. However, mice with conditional deletion
of Rad9 in skin keratinocytes are inherently susceptible to
the development of skin tumors in response to treatment
with the carcinogen 7,12-dimethylbenzanthracene
(DMBA)[19]. Thus far, there has been no report address-
ing the function of Rad1 in carcinogenesis.
To determine whether Rad1 functions to maintain
genomic stability and prevent tumor development, we
generated  Mrad1  m u t a n t  m i c e  b y  g e n e  t a r g e t i n g .
Homozygous deletion of Mrad1  leads to embryonic
lethality, but heterozygous animals have no overt defects
compared to Mrad1+/+ mice. Combined treatment with
DMBA and TPA induced skin tumors significantly more
frequently in Mrad1+/- mice than in Mrad1+/+ controls,
and also caused significantly more and larger skin tumors
in the mutant. Mrad1+/- keratinocytes contained more
double strand DNA breaks as well, suggesting that this
gene is critical for genome stabilization in keratinocytes,
and that it carries a function important for preventing
tumor development.
Results
Mouse embryonic lethality caused by Mrad1 homozygous 
deletion
To obtain Mrad1-disrupted ES cells, we used a promoter-
less gene targeting strategy to delete the gene [20]. Mrad1
was disrupted by homologous recombination in ES cells
using the targeting vector illustrated in Fig. 1A. This tar-
geting construct contains a selectable neo  gene. This
gene, which lacked the start codon (ATG), was inserted
between the third exon and third intron of Mrad1, delet-
ing parts of the third exon and third intron. Homologous
recombination of the targeting construct into mouse
genomic Mrad1 was predicted to generate mutant cells
that express a fusion protein containing the 77AA of the
Mrad1 N-terminus and a full length neo protein, but
lacking the rest of the Mrad1 protein (part of the third
exon and the complete 4, 5 and 6 exons). We then tar-
geted a 129Sv/Ev ES cell line obtained from Dr. Victor
Lin's laboratory (Columbia University) and Mrad1+/- ES
cell clones were obtained after transfection and challenge
with 300 μg/ml G418. Multiple heterozygous Mrad1-
deleted clones were identified by Southern blot analysis
(Fig. 1B). A few were selected for PCR genotyping and
confirmed to be Mrad1 heterozygous (Fig. 1C).
Mrad1+/- ES cells were used to generate Mrad1 targeted
mice (see Methods for details). Genotypes of the mice
were analyzed by Southern blot hybridization (Fig. 1D)
and PCR (Fig. 1E), and indicated that Mrad1+/- animals
were successfully generated. Mating between Mrad1+/-
mice only produced Mrad1+/+ and  Mrad1+/- offspring,
providing evidence that Mrad1-/-  causes embryonic
lethality. Mating between Mrad1+/- and  Mrad1+/+ mice
generated almost equal numbers of Mrad1+/-  and
Mrad1+/+ pups (111:109), suggesting no effect of Mrad1
heterozygous mutation on embryonic survival. Mrad1+/-
and wild type mice were maintained and monitored up to
1.5 years of age, and heterozygotes had no overt defects
compared to wild type mice.
Mouse embryos at 7.5 dpc with either the Mhus1-/- or
Mrad9-/- genotype are smaller than wild-type littermates,
look morphologically abnormal, and eventually die dur-
ing embryonic development [21,22]. To determine the
embryonic morphology and the stage of embryonic
lethality of Mrad1 homozygous mutants, embryos result-
ing from Mrad1+/- X Mrad1+/- crosses were retrieved at
different stages of gestation. We examined embryos at
6.5d, 7.5d, 8.5d, 10.5d and 11.5d. Table 1 shows the num-
bers and genotypes of the embryos obtained. PCR was
used to genotype DNA isolated from yolk sacs (Fig. 2A).
Gross morphology of embryos at the different stages of
development is presented in Fig. 2B. Mrad1-/-, Mrad1+/+
and Mrad1+/- embryos were identified at all stages ana-
lyzed. At E6.5, 23 of the 27 embryos are close in size and
morphology except 2 Mrad1-/-, 2 Mrad1+/+ and 1 Mrad1+/
-embryos were relatively smaller but with normal mor-
phology. Overall, deletion of Mrad1 does not impact on
the size and gross morphology of the embryos by E6.5. At
E7.5, however, there were many Mrad1-/- embryos signifi-
cantly smaller than those with the Mrad1+/- or Mrad1+/+
genotype. We retrieved three liters at E7.5, and the widths
of the embryos were measured. The average width among
the embryos with the same genotype was calculated, and
then normalized to the average width of wild type
embryos. Afterwards, the average widths of the embryos
from the three liters were subjected to statistical analysis
(T-test), and we found that the width of Mrad1-/- embryos
was statistically significantly smaller than that of Mrad1+/
+  embryos (P = 0.016); the widths of Mrad1+/-  and
Mrad1+/+ embryos were statistically equal (P = 0.11). At
E8.5, Mrad1+/- and Mrad1+/+ embryos were further devel-
oped while Mrad1-/- embryos still looked like the Mrad1-/
- embryos at E7.5 (data not shown). At E10.5 only amor-
phous material was found as Mrad1-/- embryos (Fig. 2B),
and at E11.5 Mrad1-/- embryos were completely resorbed.Han et al. Molecular Cancer 2010, 9:67
http://www.molecular-cancer.com/content/9/1/67
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Figure 1 Targeted deletion of Mrad1. A, Top panel: Mrad1 genomic DNA; Bottom panel: targeting construct. White boxes: exons; Gray box: promo-
torless neo gene; black thin lines: introns; Black thick lines: DNA sequences outside of Mrad1 genomic DNA; Numbers above: lengths of introns in bp; 
Numbers below: lengths of exons in bp; White arrows: restriction enzyme cutting sites (targeting construct) and locations around the DNA sequence 
to be removed (genomic DNA); B, Southern blot analysis of the Mrad1 gene in mouse ES cells. Bands indicate wild-type and deleted Mrad1 allele. C, 
PCR to assess genotypes in mouse ES cells. Bands indicate wild-type and deleted Mrad1 allele. D, Southern blot analysis of the Mrad1 gene in mice. E, 
Mrad1 genotyping in mice using PCR.Han et al. Molecular Cancer 2010, 9:67
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Taken together, as Mrad9 and Mhus1, Mrad1 is critical
for embryonic development at or before E7.5.
Mrad1 deletion enhances the incidence of mouse skin 
tumor development
To determine if Mrad1 is important for tumorigenesis,
the skin of mice with Mrad1+/+ and Mrad1+/- genotypes
was treated with DMBA plus TP A. A total of 38 mice
were divided into 2 groups, each with the Mrad1+/+ or
Mrad1+/- genotype. The 2 groups were from 19 litters,
e a c h  l i t t e r  c o n s i s t i n g  o f  2  m i c e  w i t h  Mrad1+/+  and
Mrad1+/- genotypes, and identical sex, either female (14
liters) or male (5 liters). Under this setting, Log-Rank Test
in the Kaplan-Meier PL method can be used for statistical
analysis on the significance of differences of tumor devel-
opment between two groups of animals [23]. DMBA was
used to initiate skin tumorigenesis, and TPA was used to
promote skin tumor growth. Mice were first painted with
15 μg DMBA in 100 μl acetone. One week after DMBA
treatment, mice were painted with 2 μg TPA in 100 μl
Figure 2 Gross morphology of mouse embryos derived from Mrad1+/- × Mrad1+/- crosses. A, PCR genotyping of Mrad1 in mice. Yolk sac genomic 
DNA was used as template. B, Representative gross morphology of Mrad1 mouse embryos at E6.5, E7.5 and E10.5. A complete liter of embryos at each 
stage are presented. +/+, Mrad1+/+; +/-, Mrad1+/-; -/-, Mrad1-/-.Han et al. Molecular Cancer 2010, 9:67
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acetone twice a week (Monday and Thursday) for 17
w e e k s .  O n l y  s k i n  t u m o r s  l a r g e r  t h a n  1  m m  w e r e
recorded. After 7 weeks of TPA treatment, Mrad1+/- mice
began to develop skin tumors in the treated area. It took
13 weeks of TPA treatment for the first Mrad1+/+ mouse
to develop skin tumors (Fig. 3A and 3B). At the 17th week
of TPA treatment, when the experiment ended, 14
Mrad1+/- mice had skin tumors while only 7 Mrad1+/+
mice, treated in the same fashion, developed skin tumors
(Fig. 3B). Kaplan-Meier PL method [23] was used for
comparison of the relative risk of tumor development
induced by DMBA plus TPA between mice with different
genotypes. The rate of tumor development in Mrad1+/-
mice was significantly higher than in Mrad1+/+ mice (P =
0.003, Log-Rank Test). Additionally, the average number
o f  t u m o r s  i n  e a c h  o f  Mrad1+/-  mice that developed
tumors was significantly higher (P = 0.010) than that in
tumor-bearing  Mrad1+/+ mice (Fig. 3C). We also mea-
sured the size of tumors on mouse skin after 17 weeks of
TPA treatment. Tumors larger than 6 mm in diameter
only appeared in Mrad1+/- mouse skin (Fig. 3D; data not
shown). We made skew analysis on the tumor size distri-
bution and found that G1 values were 0.40528 and
1.84488 for the wild type and Mrad1 heterozygous mice,
respectively, suggesting that Mrad1  heterozygous mice
bore significantly larger tumors. Staining skin specimens
with H&E or anti-keratin 14 indicated that the tumors
were derived from keratinocytes and possessed charac-
teristics of papillomas (Fig. 3E and 3F). All these data sug-
gest that Mrad1 plays an important role in the prevention
of skin papilloma development.
Mrad1 deletion induces spontaneous double strand DNA 
breaks
DNA repair and cell cycle control are two processes
important for maintaining genomic integrity and pre-
venting carcinogenesis [1,2], thus we investigated these
processes in keratinocytes bearing an Mrad1 deletion.
First, we examined whether there is a significant change
in the proliferation of the isolated keratinocytes resulting
from the deletion of an allele of Mrad1. Cells were grown
in defined Keratinocyte-SFM medium. Five hundred
thousand cells, either Mrad1+/+ or Mrad1+/-, were seeded
into each well of 6-well plates. The number of cells in
eac h popu la ti on dr o pped t o near ly 40% of  t he  seeded,
original number (2 × 105 per well) after the first 2 days of
incubation. Subsequently, the total number of keratino-
cytes increased until day 12 when the experiment was
terminated (Fig. 4A). There is a slight but significant dif-
ference in cell proliferation between Mrad1+/+  and
Mrad1+/- keratinocytes (at Day 12, P = 0.03). This result
indicates that Mrad1 deletion affects the normal prolifer-
ation of cells although the influence is not dramatic.
The isolated keratinocytes were cultured in an incuba-
tor for 3 days before analysis of DNA damage. The neu-
tral comet assay was used to detect DNA double-strand
breaks (DSBs). There were significantly more DSBs in the
incubated Mrad1+/- keratinocytes than inMrad1+/+ cells
(P = 0.004) (Fig. 4B). The phosphorylation of histone
H2AX (γ-H2AX), a marker for the presence of DSBs, was
also used to evaluate DSBs in Mrad1+/-and  Mrad1+/+
keratinocytes in this study. Significantly more Mrad1+/-
keratinocytes contained γ-H2AX-positive foci than
Mrad1+/+ cells, while significantly less Mrad1+/- keratino-
cytes contained no γ-H2AX foci compared to Mrad1+/+
cells (Fig. 4C). Therefore, Mrad1 is critical for maintain-
ing genomic integrity. We also studied the effects of
Mrad1 deletion on apoptosis. The percentage of apop-
totic cells among Mrad1+/- keratinocytes is slightly higher
than within theMrad1+/+ cell population (Fig. 4D), but the
difference is not statistically significant. We also exam-
ined the apoptosis levels induced by DMBA (0.15 μg/ml,
24 h), and found that the apoptosis levels in both Mrad1+/
- and Mrad1+/+ keratinocytes were enhanced, but there
were no statistically significant differences between the
DMBA-induced apoptosis levels of Mrad1+/- and Mrad1+/
+ cells, and between the mock-treated and DMBA-treated
cells with either genotypes (Fig. 4D). The above results
suggest that Mrad1  deletion in keratinocytes does not
alter DMBA-induced apoptotic response in this experi-
mental setting.
Flow cytometric analyses of PI-stained Mrad1 keratino-
cytes indicated that Mrad1+/- cells contained a slightly
smaller G1 subpopulation and a slightly larger S subpop-
Table 1: Numbers of embryos with indicated genotype.
Stage Mrad1+/+ Mrad1+/- Mrad1-/-
E6.5 8 10 9
E7.5 5 12 4
E8.5 6 17 5
E 1 0 . 5 256
E11.5 5 1 3(resorptions)Han et al. Molecular Cancer 2010, 9:67
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Figure 3 Skin tumor induction by DMBA-TPA treatment. A, Papillomas induced by DMBA-TPA treatment in Mrad1+/+ mouse skin (left) and treated 
Mrad1+/- mouse skin (right). B, Incidence of papilloma-free mice after DMBA-TPA treatment. Kaplan-Meier plot of tumor-free state as a function of time 
after DMBA painting followed by TPA treatment (blue, Mrad1+/+; red, Mrad1+/-). Mrad1+/+ and Mrad1+/- mice (n = 38) were initially treated once with 
DMBA at week 1 on the skin topically starting at ages 7 to 8 weeks, and TPA twice weekly for 17 weeks. There was a significant difference in papilloma 
formation between Mrad1+/+ and Mrad1+/- mice (P = 0.003). C, Average numbers of papillomas on each mouse (blue, Mrad1+/+; red, Mrad1+/-). Only 
papillomas larger than 1 mm diameter were counted. There was a significant difference in the number of papillomas per mouse between two the 
genotypes at the 17-week end point (P = 0.010). D, Size distribution of papillomas. The length of a papilloma was used to represent its size. E, H & E 
staining for papillomas. A typical papilloma was shown, with connective tissues extending into the tumor. F, Keratin 14 staining for keratinocytes. The 
same tumor sample in E was also stained for Keratin 14, and it was thus shown to be derived from keratinocytes.Han et al. Molecular Cancer 2010, 9:67
http://www.molecular-cancer.com/content/9/1/67
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Figure 4 Proliferation, spontaneous DNA DSBs, apoptosis and cell cycle distribution of Mrad1+/+ and Mrad1+/- keratinocytes. A, Proliferation 
of skin keratinocytes. The average results were derived from three independent experiments. B, Spontaneous DNA double strand breaks detected with 
comet assay. The mean values were derived from three independent experiments, and each was the average of assays on 50 cells. C, Spontaneous 
DNA double strand breaks detected with γ-H2AX labeling. Assessments were made by counting foci in at least 100 cells for every sample, and the 
result shown is the mean of triplicate samples for each genotype. Statistical analyses: n = 3, P = 0.007 for 0 foci, P = 0.42 for 1-5 foci and P = 0.0009 for 
more 5 foci, D. Quantitative comparison of apoptosis between Mrad1+/+ and Mrad1+/- keratinocytes mock-treated and treated with DMBA for 24 h. The 
apoptotic levels were analyzed using Annexin V labeling. E, Comparison of cell cycle distribution of Mrad1+/+ and Mrad1+/- keratinocytes mock-treated 
and treated with DMBA. The numbers above each phase indicate the percentage of cells in that phase among the whole cell population. Mrad1+/- 
cells in G1 phase were not more than Mrad1+/+ cells in G1 phase. DMBA-TPA treatment slightly arrested cells in G1 phase. F, The cell cycle distributions 
of Mrad1+/+ and Mrad1+/- keratinocytes monitored with BrdUrd uptake. The cells were stained with both PI and anti-BrdUrd. The top box indicates Br-
dUrd-positive cells, and the number in the bottom right box is the percentage of BrdUrd-negative cells with late S phase DNA content.Han et al. Molecular Cancer 2010, 9:67
http://www.molecular-cancer.com/content/9/1/67
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ulation in the cell cycle than Mrad1+/+ cells (Fig. 4E).
After incubation for 24 h in medium containing 0.15 μg/
ml DMBA, more cells with either Mrad1 phenotype were
accumulated in G1 phase (Fig. 4E), indicating a functional
G1 phase checkpoint control in both cell types. Measure-
ment of BrdUrd uptake by replicative S phase cells in
combination with DNA content via PI staining in individ-
ual cells can reveal more information on cell cycle distri-
bution. Therefore, we investigated cell cycle profiles in
more detail by pulse labeling with BrdUrd and staining
cells after 4 days of incubation. There is again no major
difference in cell cycle distribution between Mrad1+/+ and
Mrad1+/- keratinocytes. The number of BrdUrd-positive
Mrad1+/+ cells in S phase is nearly the same as the num-
ber of Mrad1+/- cells (Fig 4F). Based on the above data, we
conclude that Mrad1 deletion has only a slight effect on
the distribution of cell cycle phase during in vitro incuba-
tion in both mock-treated and DMBA-treated conditions.
This result is consistent with the finding that Mrad1 dele-
tion only leads to a slight delay in proliferation of mouse
skin keratinocytes.
Expression of the cell cycle checkpoint genes p53, p21, 
Mrad9 and Mhus1 in Mrad1+/+ and Mrad1+/- keratinocytes
In a previous study, we reported that deletion of either
one or two alleles of Mrad9 induced expression of cell
cycle checkpoint genes and dramatically reduced cell pro-
liferation of keratinocytes in culture. The results herein
show that Mrad1+/- keratinocytes have only a slightly
lower proliferation rate than the Mrad1+/+ controlcells
(Fig. 4A). We therefore examined whether expression lev-
els of p53 and p21 in Mrad1+/- keratinocytes are higher
than in the related Mrad1+/+ cells. Indeed, heterozygous
deletion of Mrad1  did not by itself alter expression of
p21or  p53  in skin keratinocytes in culture (Fig. 5A).
These results can explain why Mrad1+/- keratinocytes do
not have significantly higher levels of apoptosis and only
a slightly lower proliferation rate than those of the wild
t y p e  k e r a t i n o cyt e  c o n t r o l .  W e  f u r t h e r  i n v e s t i g a t e d  p21
and p53 expression levels in keratinocytes treated with
DMBA (0.15 μg/ml, 24 h) and found that the treatment
induced expression most dramatically of p53  but also
somewhat p21 in both Mrad1+/+ and Mrad1+/- keratino-
cytes (Fig. 5A). The expression levels of Mrad9  and
Mhus1 in keratinocytes withMrad1+/+ and Mrad1+/- gen-
otypes were also examined by real-time PCR. The results
show that Mrad9  and Mhus1 expression levels are not
altered by one allele Mrad1 deletion (Fig. 5B), suggesting
that there is no regulatory effect of Mrad1 on either
Mrad9  or  Mhus1  expression in mouse keratinocytes.
Interestingly, Mrad1 expression levels in Mrad1+/- mouse
skin tumors were higher than those in Mrad1+/+mouse
skin tumors, but not statistically significantly (Fig. 5C).
Discussion
Mouse Rad1 is homologous to Saccharomyces cerevisiae
RAD17 (scRAD17; [24,25]), Schizosaccharomyces pombe
rad1+ (sprad1+; [26-28]), Ustilago maydis REC1 [28,29]
and human Rad1 [30-34]. In yeasts, rad1 is evolutionally
conserved and a key component that mediates multiple
cellular responses to DNA damage and cell cycle check-
points [26,27,35-37]. After mouse and human Rad1 were
Figure 5 Expression of cell cycle checkpoint genes. A. Expression of 
p21 and p53 in Mrad1+/+ and Mrad1+/- keratinocytes. Western blotting 
analysis of p21 and p53 protein levels in keratinocytes incubated for 
four days after isolation. The first two lanes are the protein levels in cells 
without DMBA treatment, and the last two lanes are proteins from cells 
treated with 0.15 μg/ml DMBA for 24 hours. The data in the figure rep-
resent results from three independent western blotting experiments. 
+/+ and +/- indicate Mrad1+/+ and Mrad1+/- genotypes, respectively. B. 
Mrad9 and Mhus1 expression levels in Mrad1+/+ and Mrad1+/- keratino-
cytes. The gene expression levels were analyzed with real-time quanti-
tative RT-PCR. Each result is the average ratio of the PCR results of an 
indicated gene relative to β-actin level for three independent samples, 
and each PCR result is the mean of triplicate PCR of the same sample. 
The difference of the Mrad1 expression levels between Mrad1+/- and 
Mrad1+/- cells is statistically significant (n = 3, P = 0.022). Either Mrad9 or 
Mhus1 expression levels were similar in both Mrad1+/+ and Mrad1+/- ke-
ratinocytes. C. Mrad1 expression levels in Mrad1+/+ and Mrad1+/- tu-
mors. The expression levels of Mrad1 were analyzed by PCR as in B in 
this figure legend, and no statistical significance (n = 3, P = 0.34).Han et al. Molecular Cancer 2010, 9:67
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transfected into corresponding mutant yeast cells, cell
cycle checkpoint is restored. However, other functions of
this gene in mammals are not well established. In this
report, we examined whether Mrad1 prevents tumor for-
mation and the mechanisms involved, using keratino-
cytes of mice with deletion of one Mrad1 allele because of
the lethality caused by a Mrad1 homozygous null (Fig. 1).
We showed that Mrad1 plays important roles in embry-
onic development and is required for preventing skin
tumor formation induced by DMBA-TPA combinational
treatment (Fig. 2 and Fig. 3). Thus we identify Mrad1 as
an important genome caretaker or tumor suppressor for
skin cancer.
Mrad9-/- and Mhus1-/- are critical for embryonic devel-
opment at or before E7.5 [21,22]. We show in this study
that homozygous deletion of Mrad1 also leads to embry-
onic lethality, and to slower growth and abnormal devel-
opment at E7.5 (Fig. 2B). Therefore, the 9-1-1 (Rad9-
Hus1-Rad1) complex is likely essential for normal embry-
onic development.
Since Mrad1+/- mice have no readily observable abnor-
m a l i t i e s  u p  t o  1 . 5  y e a r s  o f  a g e ,  w e  e x a m i n e d  w h e t h e r
combined treatment with DMBA and TPA on skin can
reveal that heterozygous deletion of Mrad1 causes sus-
ceptibility to tumor development. As shown in Fig. 3A,
the heterozygous Mrad1 deletion greatly enhanced tumor
development. To understand the molecular mechanism
behind the tumor-preventing function of Mrad1, we
examined cell proliferation, DNA double strand breaks,
apoptosis and cell cycle phase distribution of Mrad1+/+
and  Mrad1+/-  keratinocytes. Our results indicate that
heterozygous deletion of Mrad1 did not increase the fre-
quency of apoptosis (minor but not statistically signifi-
cant increase), the expression of p53 and p21, and only
slightly reduced cell proliferation, although the Mrad1
deletion did induce DNA double stand breaks (Fig. 4D, A,
B and 4C; Fig. 5A). In a previous study [19], we also dem-
onstrated that heterozygous deletion of Mrad9 in kerati-
nocytes led to spontaneous DNA double strand breaks. In
addition, the heterozygous Mrad9  deletion induced
apoptosis, high levels of p53 and p21 expression, and dra-
matically slowed down cell growth, which is different
from what has been observed for the impact of Mrad1
deletion in keratinocytes. Therefore, Mrad1 and Mrad9
both prevent skin tumor development, but perhaps
through different mechanisms and not exclusively via
participation in the 9-1-1 complex. The 9-1-1 complex
plays important roles in cell cycle checkpoint control and
DNA damage repair which are important for genome sta-
bility, and thus Mrad1 and Mrad9 deletions may lead to
skin tumors via loss of their genome caretaking function.
Additional studies are needed to fully explain the mecha-
nistic details and implications of these findings with
respect to tumor prevention, and the impact on detection
and treatment of cancer.
Among the three components in the 9-1-1 complex,
human Rad9 expression has been most studied in human
tumor tissues, partly due to available good anti-human
Rad9 antibodies [13-16]. As mentioned above, the
heterozygous deletion of Mrad9  induces apoptosis and
dramatically reduces cell proliferation, the two features
which act against tumor development and are not shared
by the heterozygous deletion of Mrad1. Therefore,
human cells with abnormal expression of human Rad1 or
its malfunctioned mutations are more likely to survive
and form tumors in patients. It would be interesting to
examine Rad1 expression in human cancer tissues to find
out the role of Rad1 in human tumor development.
Surprisingly, the Mrad1  expression level in Mrad1+/-
mice is twice that in Mrad1+/+ mice although the differ-
ence is not statistically significant (Fig. 5C). However, the
facts that the both null-Mrad9 and heterozygous Mrad1
deletion enhances susceptibility for skin tumor develop-
ment, and that knockdown of highly expressed Rad9 in
human prostate tumor cells correlates with reduction of
tumorigenicity in nude mice [16] suggest the following
models. At the very early stage, unrepaired DNA lesions
enhances the opportunity for cellular genome to become
more unstable and thus for the later-stage tumor develop-
ment. A genome with extremely high instability does not
support the cell's survival and proliferation. In the case of
Mrad9 or Mrad1 deletion, mouse skin would become
susceptible for tumor development owing to enhanced
damaged cellular DNA, and in the case of human cancer,
the highly expressed Rad9 would maintain the stability of
the cancer cell genome to certain level so the cell could
survive and proliferate. Obviously much more research
work needs to be done to confirm the above models.
Methods
Targeting vector construction
A targeting vector was made to produce a deletion in
Mrad1. We used the promoterless selection strategy to
obtain a high efficiency of h o m o l o g o u s  g e n e  t a r g e t i n g
[20]. The targeting vector was constructed in three steps
starting with pBluescript SK(+) vector. First, the 5'end
fragment, a 1523 bp Mrad1 sequence between exon 2 and
exon 3, was generated by PCR from 129 SvEv mouse
genomic DNA with primers:
5'-GTCTCAGGTTTTCACACATCTTCC-3' and 5'-
CTACGCGTCGACCTTCCTGAATGACAAATTC-
CTG-3' (Fig. 1A). The PCR product was cut with Kpn1
and Sal1, and subcloned into pBluescript SK(+). Second,
the neo gene was amplified from pRc/CMV2 vector with-
out the promoter and ATG using primers:
5'-CTACGCGTCGACATTGAACAAGATGGATTG-
CACGC-3' and 5'-AAGGAAAAAAGCGGCCGCAGA-Han et al. Molecular Cancer 2010, 9:67
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CATGATAAGATACATTGATGAG-3'. Then, the PCR
product was cut with Sal1 and Not1, and inserted in
frame with Mrad1 into the plasmid constructed in the
first step. Third, the 3'end fragment, 5591 bp long
between intron 3 and intron 6, was generated by PCR
from 129 SvEv mouse genomic DNA with primers:
5'-AAGGAAAAAAGCGGCCGCCTACTACAAC-
TACTGCTACTAC-3' and 5'-TCCCCGCGGCACAG-
GACAGTACAGTAAGTCG-3'. The product was cut
with  SalI and SacII, and inserted into the vector con-
structed in the second step. This yielded the final target-
ing construct with the selectable neo  gene, which was
linearized with Kpn1 prior to transfection into ES cells.
Growth of ES cells, gene targeting, and generation of 
Mrad1-deficient cells and mice
ES cells derived from 129 SvEv mice were cultured by
established methods [38]. ES cells used to make gene-tar-
geted mice were grown on feeder cells, electroporated
with targeting vector linearized by Kpn1, and then grown
in the presence of G418 at 300 μg/ml. The G418-resistant
clones were picked, expanded and subjected to Southern
blot hybridization and PCR analyses to identify Mrad1+/-
targeted clones. Positive clones were injected into
C57BL/6 blastocysts. Chimeric offspring were born and
mated to C57BL/6 mice to confirm successful germ line
transmission of the targeted Mrad1 allele. Genomic DNA
from tails was analyzed by Southern blot hybridization
and PCR analyses. Mrad1  heterozygous mutant mice
were intercrossed and maintained.
Southern blotting and PCR assays to assess genotypes
For Southern blotting, genomic DNA was isolated from
ES cells and tails of mice using published methods [22].
DNA was digested with HindIII, separated on a 0.7% aga-
rose gel, then transferred to a nylon membrane, and
hybridized to a 32P-labeled probe, which was generated
by PCR using primers:
5'-GTGGCCTAGGTGGTTGCGTATCTGAAC-3' and
5'-GTCGGCTCCGAGAAGAAGGATGCTCC-3' in con-
junction with mouse genomic DNA as template.
To genotype ES cells and mice by PCR, the reaction was
performed using genomic DNA templates and the follow-
ing primer pair:
5'-GTCTCAGGTTTTCACACATCTTCC-3' and 5'-
GCTTATATTCTAGAAACCTTCCTGTATG-3'. PCR
conditions were 95°C for 5 min, followed by 35 cycles of
95°C for 30 s, 59°C for 30 s, and 72°C for 3 min, with a
final extension at 72°C for 10 min.
Morphological analysis of mouse embryos
Mouse embryos were obtained at several stages of gesta-
tion, including E6.5, E7.5, E8.5, E10.5, and E11.5. All dis-
sections were performed in 1 × PBS. Whole embryos
were rinsed with 1 × PBS. Pictures of whole embryos
were taken while viewed by a Wild Heerbrugg dissecting
microscope.
Preparation and in vitro culture of keratinocytes
Full-thickness skin removed from newborn (1-2 days old)
mice was treated with 0.25% trypsin overnight at 4°C.
The epidermis was peeled off from the dermis and
minced into pieces smaller than 1 mm. They were placed
into a sterile flask, then dispersed by stirring into single
cells for 30-60 min, then suspended in Keratinocyte-SFM
medium with supplements (Invitrogen). Cells were first
incubated in dishes coated with collagen type I at 34°C in
5% CO2 for 12 h to allow cells to attach to the bottom.
Afterwards, unattached cells were removed by washing
with PBS. Attached cells were further cultured in fresh
medium, which was replaced every 2 days.
Western blotting
For preparing protein from epidermis, full-thickness skin
removed from newborn mice was treated with 0.25%
trypsin overnight at 4°C. The epidermis was peeled off
from the dermis and dispersed in lysis buffer. To prepare
cell lysate, keratinocytes incubated for 3 days were either
left untreated or treated for 24 h with 0.15 μg/ml DMBA
(Sigma). Then, the cell lysate was prepared in 1× SDS-
sample buffer, to a final concentration of 104 cells/μL.
Fifty μg of protein were resolved on a 10% SDS-PAGE gel,
and proteins were transferred to a polyvinylidene difluo-
ride membrane. The membrane was probed consecu-
tively with primary and peroxidase-conjugated secondary
antibodies. Primary and secondary antibodies used in
this study are mouse anti-GAPDH (KangChen, China),
mouse anti-p21 (Santa Cruz), mouse anti-p53 (Onco-
gene), peroxidase-conjugated anti-rabbit IgG (A9169,
Sigma) and peroxidase-conjugated anti-mouse IgG
(A9044, Sigma).
DMBA-TPA induced skin tumor formation
Mice (7-8 weeks old) were shaved on their backs 2 days
before tumor induction. To induce tumors, the shaved
dorsal skin of mice was treated topically with 15 μg of
DMBA (Sigma) in 100 μL acetone once. After 1 week,
each animal received subsequent topical treatments of 2
μg of TPA (Sigma) in 100 μL acetone twice weekly for 17
weeks. Treated areas were examined weekly for the pres-
ence of tumors, which were scored positive if they
reached at least 1 mm in diameter.
Histologic analysis and Immunohistochemistry
Dorsal skin samples and tumors were fixed in 4% para-
formaldehyde at 4°C overnight, embedded in paraffin,
and sectioned as 8-μm slices. The sectioned tissues on
slides were stained with H&E [39,40]. Immunohis-
tochemical staining was carried out using a kit (Immu-Han et al. Molecular Cancer 2010, 9:67
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noCruz Staining Systems, Beijing Zhongshan Golden
Bridge Biotechnology). The endogenous peroxidase
activity in the specimens was blocked by treatment with
0.3% H2O2 and samples were then rinsed with PBS. The
specimens were probed consecutively with primary anti-
bodies against Keratin 14 (BAbCo), secondary antibody
biotin-conjugated goat anti-rabbit IgG, and horseradish
peroxidase-streptavidin complex, and then visualized by
diaminobenzidine. Afterwards, sections were counter-
stained with hematoxylin.
Proliferation assay
Keratinocytes were isolated as described above and
seeded into 6-well plates (5 × 105 cells per well) contain-
ing Keratinocyte-SFM medium with supplements. Cell
numbers were determined every 2 days.
Cell cycle analyses
The cell cycle profiles of cells in different phases were
determined using previously established methods [41].
Briefely, 1 × 107 keratinocytes were plated in each 10-cm
dish. After incubation for 3 days the cells were mock-
treated or treated with 0.15 μg/ml DMBA (Sigma) for 24
h, then processed and stained with propidium iodide (PI),
and analyzed by a FACSCalibur cytometer (Becton Dick-
inson). To assess DNA synthesis, 10 μM BrdUrd was
added to medium and cells were pulse labeled for 40 min.
Cells were then processed, probed with FITC-conjugated
anti-BrdUrd antibody (Becton Dickinson) and stained
with PI. Flow cytometric analyses were performed on a
FACSCalibur.
Apoptosis assay
Keratinocytes incubated for 4 days were mock-treated or
treated for 24 h with 0.15 μg/ml DMBA, trypsinized for
10 min using 0.1% trypsin at 37°C, washed twice with
cold PBS, then resuspended in 1× binding buffer [10
mmol/L HEPES (pH 7.4), 140 mmol/L NaCl, and 2.5
mmol/L CaCl2] at a concentration of 1 × 106 cells/mL.
Then cells were stained with Annexin V-FITC (Jingmei
Biotech) and PI for 15 min at room temperature before
flow cytometric analysis.
Neutral comet assay
Keratinocytes were cultured in standard medium for 4
days. The comet assay was carried out according to the
manufacturer's instructions (Trevigen). Briefly, cells at a
concentration of 1 × 105/mL were mixed gently with pre-
melted low-temperature-melting agarose at a volume
ratio of 1 to 10 (v/v) and spread on glass slides. The slides
were then submerged in precooled neutral lysis buffer at
4°C for 30 min. After rinsing, the slides were equilibrated
in Tris-borate EDTA solution, electrophoresed at 1.0 V/
cm for 20 min, and then stained with PI. Fluorescence
images for at least 50 nuclei were captured using a Nikon
microscope and analyzed by CASP-1.2.2 software (Uni-
versity of Wroclaw) for tail moment (i.e., the geometric
mean of fluorescence on the tail from the nucleus).
Statistical analysis
All statistical analyses were performed using statistical
software package SPSS Version 10.0. The Kaplan-Meier
PL method [23] was used for comparison of the relative
risks of tumor development induced by DMBA-TPA
between the mice with the two different Mrad1 geno-
types. We designed the tumor development experiment
to meet a set of conditions so the Log-Rank Test in the
Kaplan-Meier PL method could be used. The Student's t
test was performed to determine statistical significance of
the differences for the comet assay. Wilcoxon rank-sum
test was used to compare the difference in tumor num-
bers between the two groups of mice having different
Mrad1 genotypes. In all the above analyses, a P value of <
0.05 was considered statistically significant. Skewness
was used to compare the difference of tumor size distri-
butions between Mrad1  wild type and heterozygous
mice.
Immunofluorescence assay
Keratinocytes grown on coverslips were fixed with 4%
paraformaldehyde in PBS for 15 min at room tempera-
ture, washed in PBS twice, incubated in PBS containing
0.5% Triton-X100 for 15 min and in PBS containing 5%
BSA and 0.1% Triton-X100 for 1 hr, and washed in PBS
once, followed by incubation with anti-phospho-H2AX
(Upstate) primary antibody (1:100 dilution) in PBS con-
taining 5% BSA and 0.1% Triton-X100 for 1 hr at room
temperature. Afterwards, the coverslips were washed two
times for 5 min each in PBS and incubated with Texas
Red -conjugated anti-mouse antibody (1:100 dilution in
PBS containing 5% BSA and 0.1% Triton-X100) for 1 hr at
room temperature. Finally, the coverslips were counter-
stained with DAPI (10 ng/ml). The images were captured
using a fluorescence microscope.
Quantitative real-time RT-PCR
Total RNA was isolated from mouse tumors (3 wild type
and 3 Mrad1 heterozygous tumors) or keratinocytes cul-
tured for 4 days using the RNeasy Mini kit, as described
by the manufacturer (QIAGEN). Two μg total RNA were
reverse transcribed in a 20 μL reaction volume to form
cDNA using the SuperScript First-Strand Synthesis Sys-
tem for RT-PCR (Invitrogen). Real-time PCR was per-
formed using the StepOnePlus system(ABI) with SYBR
Green I (Takara) to label amplified DNA. A standard
curve method of quantification was used to calculate the
expression of target genes relative to the housekeeping
gene  β-actin. Experiments were performed thrice. TheHan et al. Molecular Cancer 2010, 9:67
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following primer pairs were used for the PCR reactions:
Mrad9, 5'-GCCTCTTACTATCCACTTCG-3' and 5'-
AGCCCTCATTGCCTCC-3';  Mrad1, 5'-GCCCT-
ATTTCAGGTTGT-3' and 5'-TGCCCATCTTCATTT
CT-3'; Mhus1, 5'-TCCCTGTCTTACCGTGTC-3' and 5'-
CTCCCTTTAGGTTTGCTT-3';  β-actin, 5'-GTAAAGA
CCTCTATGCCAACA-3' and 5'-GGACTCATCGTACT
CCTGCT-3'. We used the following PCR procedure: 94°C
for 3 min, then 40 cycles of 94°C for 15 s, 55°C for 20 s,
72°C for 19 s, and a final extension at 72°C for 3 min.
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